← Back to Search

Other

SRF617 for Prostate Cancer

Phase 2

Waitlist Available

Research Sponsored by Surface Oncology

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 24 months

Awards & highlights

Study Summary

This trial will look at the safety and preliminary efficacy of SRF617 in combination with etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate cancer (mCRPC).

Eligible Conditions

Metastatic Castration Resistant Prostate Cancer
Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence and severity of adverse events (AEs) based on treatment-emergent AEs (TEAEs)

The proportion of patients with an objective PSA (prostate-specific antigen) or radiologic response per PCWG3 criteria

Secondary outcome measures

Antidrug Antibodies (ADAs)

Disease control rate (DCR)

Duration of response (DOR)

+9 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: SRF617 in combination with etrumadenant and zimberelimabExperimental Treatment3 Interventions

All patients will receive SRF617 administered in combination with etrumadenant (AB928) and zimberelimab (AB122).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

SRF617

2022

Completed Phase 2

~100

etrumadenant

2022

Completed Phase 2

~60

zimberelimab

2022

Completed Phase 2

~20

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Surface OncologyLead Sponsor

5 Previous Clinical Trials

674 Total Patients Enrolled

Arcus Biosciences, Inc.Industry Sponsor

41 Previous Clinical Trials

6,051 Total Patients Enrolled

Lauren Harshman, MDStudy ChairSurface Oncology

2 Previous Clinical Trials

394 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any North American locations where this experiment is being conducted?

"This clinical trial is being hosted at 8 different sites, including START Mountain Region, Utah Cancer Specialists in West Valley City and Comprehensive Cancer Centers of Nevada in Las Vegas. Additionally, the University of Miami - Sylvester Comprehensive Cancer Center will be taking part as well as other medical centres across America."

Answered by AI

Has SRF617 been given the stamp of approval by the FDA?

"SRF617 has been assigned a safety rating of 2 since there is available data confirming its security, yet no evidence to support the effectiveness."

Answered by AI

Is recruitment for this trial still open?

"Per the data hosted on clinicaltrials.gov, this experiment is not currently taking in new trial members. Its first post date was January 17th 2022 and its final update took place November 28th of the same year. Nonetheless, there are still 1321 investigations recruiting patients at present."

Answered by AI

What results is the research team expecting to observe?

"This medical experiment will track the incidence and severity of adverse reactions, prostate-specific antigen levels, minimal concentrations of SRF617 in serum prior to subsequent doses, as well as antidrug antibodies for a period lasting up to two years. These metrics compose its primary outcomes whereas changes in PSA across the trial interval and percentage of patients with ADAs constitute secondary objectives."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

2022. "Study of SRF617 With AB928 (Etrumadenent) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05177770.